Abstract: Provided herein are, inter alia, antibodies capable of binding Structural Maintenance of Chromosome-1 (SMC1). The antibodies provided herein include novel light chain and heavy chain sequences and bind SMC1 (e.g., SMC1A or SMC1B) with high efficiency and specificity. The SMC1 antibodies provided herein including embodiments thereof may be used for diagnostic and therapeutic purposes, for example, as humanized SMC1 antibodies, antibody drug conjugates or they may form part of bispecific antibodies or chimeric antigen receptors.

Abstract: Provided herein are compositions including methylene bis[4,4?-(2-chlorophenylureidophenoxyisobutyric acid)] (LR-90) or a pharmaceutically acceptable salt or derivative thereof and methods of use thereof for treating and/or preventing chemotherapy-induced neuropathic pain in a subject in need thereof.

Abstract: Disclosed herein are methods of preventing and treating GVHD and autoimmune diseases. The methods entail administering one or more doses of an effective amount of a therapeutic agent to a subject to in vivo knock down Stat3 in the T cells and/or B cells of the subject. Alternatively, the methods entail contacting donor T cells and/or B cells with an effective amount of a therapeutic agent to in vitro knock down Stat3 and administering the Stat3-deficient T cells and/or B cells to the subject. Some examples of the therapeutic agent include small molecule Stat3 inhibitors such as Stat3 siRNAs delivered by an antibody to specifically knock down Stat3 in the lymphocytes of the target tissue.

Abstract: A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendible 3?-deoxynucleotide at its 3? terminus. PAP can be applied for exponential amplification or for linear amplification. PAP can be applied to amplification of a rare allele in admixture with one or more wild-type alleles by using an activatable oligonucleotide P* that is an exact match at its 3? end for the rare allele but has a mismatch at or near its 3? terminus for the wild-type allele. PAP is inhibited by a mismatch in the 3? specific sequence as far as 16 nucleotides away from the 3? terminus. PAP can greatly increase the specificity of detection of an extremely rare mutant allele in the presence of the wild-type allele.

Abstract: A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendible 3?-deoxynucleotide at its 3? terminus. PAP can be applied for exponential amplification or for linear amplification. PAP can be applied to amplification of a rare allele in admixture with one or more wild-type alleles by using an activatable oligonucleotide P* that is an exact match at its 3? end for the rare allele but has a mismatch at or near its 3? terminus for the wild-type allele. PAP is inhibited by a mismatch in the 3? specific sequence as far as 16 nucleotides away from the 3? terminus. PAP can greatly increase the specificity of detection of an extremely rare mutant allele in the presence of the wild-type allele.